Stay updated on Talazoparib-Irinotecan Combo in Pediatric Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Talazoparib-Irinotecan Combo in Pediatric Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Talazoparib-Irinotecan Combo in Pediatric Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:53:41.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the ongoing study to determine the maximum tolerated doses of talazoparib combined with irinotecan in children with refractory or recurrent solid malignancies, aiming to find effective treatments and understand potential side effects.
    Difference
    0.1%
    Check dated 2024-06-06T14:30:25.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    38%
    Check dated 2024-05-22T21:12:52.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T21:59:03.000Z thumbnail image

Stay in the know with updates to Talazoparib-Irinotecan Combo in Pediatric Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Talazoparib-Irinotecan Combo in Pediatric Solid Tumors Clinical Trial page.